

# Report of the APhA and APhA-ASP Houses of Delegates

Andrew Bzowickyj, Julie Oestreich, and Loren Madden Kirk

## APhA-APPM

The sun shined bright over this year's APhA Annual Meeting and despite the beautiful weather, your dedicated representatives were bunkered up in the windowless ballrooms of the San Diego Convention Center thoroughly discussing several pressing issues facing the profession of pharmacy. Below is a summary of the policies that were passed by the APhA House of Delegates from the perspective of the APhA Academy of Pharmacy Practice and Management. The complete wording of these policies is available at [www.pharmacist.com/house-of-delegates](http://www.pharmacist.com/house-of-delegates) and in the House of Delegates report in this issue of *JAPhA*.



Bzowickyj

## Interoperability of communications among health care providers to improve quality of patient care

Despite enhancements in interoperable communications between different health care settings and electronic systems over the years, several barriers persist that inhibit collaboration of health care professionals across all settings. This affects many aspects of patient care, including medication/patient safety, transitions of care, and pharmaceutical waste, in addition to contributing to overall inefficiencies within the health care system.

This policy emphasizes that pharmacists desperately need to be more connected with the rest of the health care system to improve the

overall health of the public and efficiency of the system. Pharmacists can help advance patient care and patient safety through adequate access to complete patient information and records.

## Integrated nationwide prescription drug monitoring program

Currently, 49 states, the District of Columbia, and Guam have legislation authorizing a prescription monitoring program (PMP) in order to decrease the abuse and misuse of controlled substances.<sup>1</sup> Missouri continues to stand alone as the only state without active legislation authorizing a PMP. Furthermore, several states are participating in the National Association of Boards of Pharmacy (NABP) PMP Interconnect,<sup>2</sup> which allows for a secure exchange of PMP data across state

lines to further reduce interstate doctor-shopping.

With this policy, pharmacists can look forward to further integration of different state-specific PMPs and calls for interprofessional advisory boards to make better use of the aggregate data. With a nationwide PMP, pharmacists can be well positioned to help alleviate the public health emergency of abuse and misuse of controlled substances.

## Role of the pharmacist in care of patients using cannabis

There was much debate regarding this topic from a variety of perspectives along the supply chain, including research, production, dispensing, and counseling. There was a large amount of agreement surrounding the need for more rigorous research on the medical benefits of cannabis and the alignment of state and federal laws.

However, the debate over the pharmacist's role in dispensing was met with some heated resistance at first. This element of the policy initially failed to pass out of the House until a brave individual from within the student pharmacist delegation resurrected the statement, which



The **Association Report** column in *JAPhA* reports on activities of APhA's three academies and topics of interest to members of those groups.

The **APhA Academy of Pharmacy Practice and Management (APhA-APPM)** is dedicated to assisting members in enhancing the profession of pharmacy, improving medication use, and advancing patient care. Through the APhA-APPM Special Interest Groups (SIGs), the Academy provides members a mechanism to network and support the profession by addressing emerging issues. To access a listing of APhA-APPM SIGs, visit [www.pharmacist.com](http://www.pharmacist.com).

The mission of the **APhA Academy of Pharmaceutical Research and Science (APhA-APRS)** is to stimulate the discovery, dissemination, and application of research to improve patient health. Academy members are a source of authoritative information on key scientific issues and work to advance the pharmaceutical sciences and improve the quality of pharmacy practice. Through the three APhA-APRS sections (Clinical Sciences, Basic Pharmaceutical Sciences, and Economic, Social, and Administrative Sciences), the Academy provides a mechanism for experts in all areas of the pharmaceutical sciences to influence APhA's policymaking process.

The mission of the **APhA Academy of Student Pharmacists (APhA-ASP)** is to be the collective voice of student pharmacists, to provide opportunities for professional growth, to improve patient care, and to envision and advance the future of pharmacy.

The Association Report column is written by Academy and section officers and coordinated by *JAPhA* Executive Editor L. Michael Posey of the APhA staff. Suggestions for future content may be sent to [mposey@aphanet.org](mailto:mposey@aphanet.org).



Consumer  
Healthcare

FOR MORE COMPLETE ALLERGY RELIEF\*...



\*Total nasal symptom relief vs. single-ingredient Claritin® 10 mg.  
Claritin® is a registered trademark of Bayer.



Works to block  
**6** key inflammatory mediators,  
not just histamine<sup>†1-4</sup>

- histamine
- cytokines
- leukotrienes
- chemokines
- prostaglandins
- tryptases

Available in 60- and  
120-metered spray bottles.

<sup>†</sup> Mechanism vs. OTC allergy pills. FLONASE acts on multiple inflammatory substances (histamine, prostaglandins, cytokines, tryptases, chemokines, and leukotrienes). The exact number and precise mechanism are unknown.

**References:** 1. Derendorf H, Meltzer EO. Molecular and clinical pharmacology of intranasal corticosteroids: clinical and therapeutic implications. *Allergy*. 2008;63 (10):1292-1300. 2. Hallgren J, Pejler G. Biology of mast cell tryptase: an inflammatory mediator. *FEBS J*. 2006;273(9):1871-1895. 3. Broide DH. The pathophysiology of allergic rhinoconjunctivitis. *Allergy Asthma Proc*. 2007;28(43):398-403. 4. Ratner PH, van Bavel JH, Martin BG, et al. A comparison of the efficacy of fluticasone propionate aqueous nasal spray and loratadine, alone and in combination, for the treatment of seasonal allergic rhinitis. *J Fam Pract*. 1998;47(2):118-125.

FLONASE, the FLONASE logo, the bottle and cap designs, and other design elements are trademarks of the GSK group of companies.

©2015 GSK group of companies. All rights reserved. Printed in USA. CHUS/CHFLO/0190/15 April 2015



**NOW AVAILABLE OTC**  
Visit **FLONASEprofessional.com**

Download English Version:

<https://daneshyari.com/en/article/2542901>

Download Persian Version:

<https://daneshyari.com/article/2542901>

[Daneshyari.com](https://daneshyari.com)